COMMUNIQUÉS West-GlobeNewswire

Guerbet : Chiffre d’affaires 2025.
05/02/2026
Chiffre d’affaires 2025 Chiffre d’affaires annuel : 786,4 M€, soit un repli de 3,5% à TCC 1 et périmètre comparable 2 , largement dû à la baisse de l’activité en France Au quatrième trimestre, une baisse de 5,6% à TCC [...]
Le plan d’action Diriger pour combler l’écart demande aux acteurs au pouvoir partout au pays de réduire les disparités en matière de santé des femmes
05/02/2026
Un nouveau plan national présente comment le Canada peut améliorer la santé des femmes et renforcer leur participation à la société afin de faire de nouveaux gains économiques TORONTO, 05 févr. 2026 (GLOBE NEWSWIRE) -- [...]
Cross Medical Group Announces New Villanova Office Location
05/02/2026
Move Reflects the Philadelphia Area Practice’s Ongoing Commitment to Patient Care VILLANOVA, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cross Medical Group, a cosmetic surgery practice specializing in procedures for the [...]
Organic & Natural Health Association Honors SENPA’s Debra Short with Champion Award at Conference Shaping Policy, and the Future of Retail
05/02/2026
FT. LAUDERDALE, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Organic & Natural Health Association ’s 11th annual conference, “The United States of Health: Building Bridges to Opportunity,” concluded Jan. 22 with a [...]
Virbac : Déclaration d'actions et de droits de vote 01/2026
05/02/2026
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers
05/02/2026
Bagsværd, Denmark and Plainsboro, NJ, 5 February 2026 – Novo Nordisk today issued the following statement regarding the announcement by Hims & Hers that they will unlawfully mass-market an unapproved, inauthentic, [...]
Guerbet : 2025 revenue.
05/02/2026
2025 revenue Full-year revenue: €786.4 million, down 3.5% at CER 1 and on a like-for-like basis 2 , largely due to the fall in business in France A decline in Q4 of 5.6% at CER and on a like-for-like basis, linked to [...]
Chiesi Global Rare Diseases Reinforces Long-Term Commitment to the Rare Disease Community with Multiple Abstract Presentations at the 22nd Annual WORLDSymposium™
05/02/2026
-- Chiesi’s abstract presentations will focus on clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- These scientific contributions in lysosomal storage disorders (LSDs) [...]
Chiesi Global Rare Diseases Reinforces Long-Term Commitment to the Rare Disease Community with Multiple Abstract Presentations at the 22nd Annual WORLDSymposium™
05/02/2026
-- Chiesi’s abstract presentations will focus on clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- These scientific contributions in lysosomal storage disorders (LSDs) [...]
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
05/02/2026
FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) [...]
Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at Scripps’ Structural Heart Intervention and Imaging 2026 Conference
05/02/2026
FORT MILL, S.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture [...]
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
05/02/2026
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed [...]
Alignment Healthcare to Announce Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call Thursday, Feb. 26, 2026
05/02/2026
ORANGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its fourth quarter and full-year 2025 financial results on Thursday, Feb. 26, 2026, after market close. Following [...]
Profusa Announces 1-for-75 Reverse Stock Split
05/02/2026
BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the [...]
Erasca to Present at Upcoming Conferences in February
05/02/2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
LB Pharmaceuticals Announces $100.0 Million Private Placement
05/02/2026
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar [...]
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
05/02/2026
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Primmune Therapeutics Appoints Chief Medical Officer and Executive Board Chair; Establishes Melanoma Clinical Study Advisory Board
05/02/2026
Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growth SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Primmune Therapeutics, Inc. , a biotech company harnessing [...]
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
05/02/2026
Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and [...]

Pages